The global prevalence of overweight and obesity has risen substantially over the past 4 decades and is accompanied by an increasing burden of cardiovascular risk factors such as hypertension. Metabolic surgery is the most effective method to treat obesity and may further improve associated conditions. Although most research has been directed toward the glycemic effects of weight loss surgery, there has been a growing interest in exploring its potential blood pressure-reducing properties. Systematic reviews and meta-analyses based primarily on observational data have suggested that metabolic surgery may aid in controlling hypertension. Only one randomized controlled trial specifically addressing this concept has been conducted, though supportive of the findings from observational studies. We review contemporary procedures for weight loss and their effects on cardiometabolic risk, particularly hypertension. In addition, we describe potential pathophysiological mechanisms and the effects of metabolic surgery on cardiovascular events and mortality. (Circ Res.
Obesity and Cardiovascular Risk
The global prevalence of overweight and obesity has increased substantially over the past 4 decades. 1 Obesity, defined by the World Health Organization as a body mass index (BMI) ≥30 kg/m 2 , has already reached epidemic proportions and affected ≈14% of the world population in 2016. 2 Although rising trends in children's and adolescents' BMI appear to have peaked in many high-income countries, they have accelerated in certain parts of Asia. Thus, if post-2000 trends continue, the global obesity prevalence is projected to reach 20% by 2025. 3 The increasing prevalence of obesity is accompanied by an increased load of type 2 diabetes mellitus, a burden that is expected to rise substantially during the next decade. 4, 5 Similarly, the risk of hypertension is significantly greater among individuals with obesity. 6 Indeed, in 2015, the global prevalence of raised blood pressure, that is, a systolic blood pressure ≥140 mm Hg or a diastolic blood pressure ≥90 mm Hg, had surpassed 20% in both men and women. 7 Furthermore, high systolic blood pressure was ranked the leading risk factor for deaths and disability-adjusted life-years in 2017. 8 Given these metabolic and hemodynamic alterations, obesity expectedly increases the risk of manifest cardiovascular disease. 9, 10 The 2015 Global Burden of Disease Obesity Collaborators report attributed ≈7% of worldwide deaths from any cause and 120 million disability-adjusted life-years to a high BMI >25 kg/m 2 , and most of this increased morbidity and mortality was caused by cardiovascular disease. 1 Metabolic surgery is the most effective method to treat obesity and may further improve associated conditions, including hypertension. [11] [12] [13] Its increasing importance is also acknowledged by the American Heart Association (AHA). 14 In this review, we describe current metabolic surgical procedures, their indications, and the effects of these procedures, particularly on blood pressure, cardiovascular outcomes, and mortality.
Conventional Treatment of Hypertension
The definition of hypertension differs between contemporary guidelines. The 2018 European Society of Cardiology/ European Society of Hypertension guidelines still adhere to the conventional definition of hypertension, that is, an office systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg. 15 In contrast, the 2017 American College of Cardiology/AHA guideline defines hypertension as a systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥80 mm Hg. 16 In most patients with an elevated office blood pressure, the diagnosis of hypertension should be confirmed by serial, temporally spaced measurements, or, when deemed logistically and economically feasible, by using either ambulatory blood pressure monitoring or home blood pressure measurements. 15, 16 Lifestyle modification is indicated for all patients with hypertension. [15] [16] [17] This encompasses dietary adjustments, weight loss, exercise, and lowering of alcohol consumption. Dietary recommendations include a reduced intake of sodium, saturated and trans fats, and red meat as well as an increased intake of potassium, fruits, vegetables, whole grains, nuts, fish, unsaturated fatty acids, and low-fat dairy products. Body weight should ideally be controlled to reach a healthy BMI (≈20-25 kg/m 2 ) or waist circumference (<94 cm in men and <80 cm in women). In fact, there is a dose-response relationship of almost 1 mm Hg drop of blood pressure per kilogram of weight loss. 18 If weight loss cannot be achieved, weight stabilization is a reasonable option. Furthermore, a greater BMI may be considered in subjects older than 60 years of age. The aerobic subtype of exercise (endurance training) is most effective for blood pressure reduction among hypertensive individuals. 19 The European Society of Cardiology/European Society of Hypertension recommends participation in at least 30 minutes of moderate-intensity dynamic exercise 5 to 7 days per week, 15 whereas the American College of Cardiology/AHA recommends 90 to 150 minutes weekly, attaining 65% to 75% of the maximal heart rate. 16 Alcohol intake should be restricted to <14 units weekly for men and <7 units weekly for women. Binge drinking should also be avoided. [15] [16] [17] Nonpharmacological remedies may be adequate in patients with mild hypertension. However, they cannot stand alone in those with target end-organ damage (hypertensionmediated organ damage), manifest cardiovascular disease, or a high calculated risk for cardiovascular disease. 15, 16 Indeed, antihypertensive medication is usually required for achieving recommended blood pressure targets. The 4 primary drug classes include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers (most often dihydropyridines), and thiazide or thiazidelike diuretics. 15, 16 These agents appear to have similar blood pressure-reducing abilities and comparable global cardiovascular protective effects. [20] [21] [22] [23] β-blockers are not recommended as first-line monotherapy, unless a specific condition necessitates their use, for example, stable angina or heart failure with reduced ejection fraction. 15, 16 In subjects with a systolic blood pressure >20 mm Hg or a diastolic blood pressure >10 mm Hg above their treatment goal, combination therapy with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker plus a calcium channel blocker or a diuretic should be initiated to improve the speed, efficiency, and predictability of blood pressure control. 15, 16, 24 The American College of Cardiology/AHA generally recommends a blood pressure goal of <130/80 mm Hg. 16 The European Society of Cardiology/European Society of Hypertension recommends that the first objective be to lower blood pressure to <140/90 mm Hg and, if tolerated, to target to ≤130/80 mm Hg in most cases. 15 It is not uncommon for clinicians to encounter patients who are difficult to treat with conventional measures. 25, 26 This includes patients with obesity or large weight gain, possibly because of correlations with sodium retention, increased sympathetic nervous system activity, and renin-angiotensinaldosterone system activation. 27, 28 The American College of Cardiology/AHA defines resistant hypertension as an office blood pressure ≥130/80 mm Hg in patients prescribed ≥3 antihypertensive medications at optimal doses or <130/80 mm Hg in patients requiring ≥4 agents. 16 The European Society of Cardiology/European Society of Hypertension recommends that hypertension resistant to treatment be defined when optimal doses of an appropriate therapeutic strategy (usually 3 drugs) are unable to lower office blood pressure to <140/90 mm Hg. 15 Obese individuals are much more likely to require ≥3 antihypertensive medications. For instance, the HYDRA study (Hypertension and Diabetes Risk Screening and Awareness) found a >5-fold greater probability of requiring 3 antihypertensives (and a >3-fold greater probability of requiring 4 antihypertensives) to achieve adequate blood pressure control <140/90 mm Hg in those with a BMI >40 kg/m 2 . 29 Resistant hypertension should be confirmed using out-of-hospital measurements and after excluding pseudo-resistant hypertension and secondary hypertension. 15, 16 Accordingly, the true prevalence is probably substantially lower than 10%. Patients with resistant hypertension have a significantly increased risk of cardiovascular events. 30 Treatment strategies include reinforcement of lifestyle measures and add-on antihypertensives, particularly a mineralocorticoid receptor antagonist. 15, 16, 31 
Metabolic Surgery
Metabolic procedures comprise the most frequently performed gastrointestinal operations. According to the latest survey conducted by the International Federation for the Surgery of Obesity and Metabolic Disorders, the total number of metabolic surgeries performed worldwide in 2016 was 685 874, up by >100 000 compared with 2014. 32, 33 Of these, ≈93% were primary procedures.
The 4 procedures currently performed in the United States (in descending order of frequency) encompass Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), adjustable gastric banding (AGB), and biliopancreatic diversion 
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with duodenal switch (BPDDS; Figure 1 ). [33] [34] [35] [36] [37] Globally, one-anastomosis gastric bypass now appears to be performed more frequently than AGB. 33 However, it is mainly performed in Europe and in the Asia-Pacific region. All procedures are usually done laparoscopically. Although it is now recognized that factors involved in weight loss are multiple and complex, the procedures have traditionally been grouped into restrictive or hybrid approaches. 38 Restrictive approaches, that is, AGB and SG, reduce gastric volume and thereby limit food ingestion, whereas hybrid surgeries (RYGB and BPDDS) also bypass portions of the intestine leading to malabsorption.
Globally, SG makes up 54% of all weight loss procedures performed. 33 SG is a longitudinal resection of about threequarters of the greater gastric curvature, from 5 to 6 cm from the pylorus to the fundus close to the cardia. This results in a tubular gastric reservoir with a volume ≈150 mL (Figure 1 ). [34] [35] [36] Important consequences are removal of most of the endocrine mucosa, increased gastric emptying, and accelerated nutrient entry into the distal small intestine, all of which ultimately lead to altered hormonal responses mimicking those seen after RYGB, possibly with a greater effect on appetite suppression caused by removal of the majority of ghrelin-producing cells in the fundus. 39, 40 RYGB was formerly the most common metabolic operation. 32, 33 It now comprises 30% of all weight loss surgeries currently performed, down by 10% since 2014. The stomach is stapled, creating a 20-to 30-ml proximal pouch that is disconnected from the more distal portion. This pouch is connected to the small intestine, 50 to 75 cm distal to the angle of Treitz. Anastomosis of the proximal intestinal segment to the jejunum more distally results in an alimentary loop (Roux limb) of around 100 to 150 cm (Figure 1 ). This allows nutrients to bypass the duodenum and proximal jejunum and flow directly from the gastric pouch into the mid-jejunum, without encountering bile and pancreatic juice. [34] [35] [36] Besides the restrictive and malabsorptive effects, these changes also modify gut hormone secretion, particularly of those involved in appetite regulation and glucose metabolism. 39, 41 AGB is the classic restrictive procedure in which an inflatable band device is implanted proximally, just below the gastroesophageal junction, creating a 30-mL upper gastric pouch. The band is connected to a reservoir port placed subcutaneously. This allows injection or removal of saline to adjust the diameter and thereby the degree of tightening of the stomach (Figure 1 ). The operation is less invasive, and the gastric and intestinal nutrient passage is not affected. Moreover, hormonal changes do not appear to account for the weight loss observed after AGB. Indeed, patients who undergo RYGB or SG experience significantly greater weight losses than those who undergo AGB, and there is an immediate weight gain if the band is not properly adjusted or removed. [34] [35] [36] 39 In fact, more than half of AGB devices need removal or conversion to another procedure because of insufficient weight loss or complications. 42 Ten years ago, AGB was the second most common metabolic procedure. However, in the latest International Federation for the Surgery of Obesity and Metabolic Disorders survey, its proportion had decreased to ≈3% of metabolic procedures worldwide. 33 BPDDS is technically challenging, and few surgeons are proficient in performing it. 35 Indeed, BPDDS only represented 0.5% of all metabolic surgeries in 2016. 33 This malabsorptive procedure requires reducing the gastric capacity through SG and transection of the duodenum ≈4 cm distally from the pylorus with subsequent anastomosis to a 250-cm ileal limb. The proximal ileum (biliopancreatic limb) is anastomosed to the ileum at 100 cm from the ileocecal valve (Figure 1) . [34] [35] [36] 43 Pancreatic enzymes and bile thus enter the distal ileum. The degree of fat and protein malabsorption is more pronounced after BPDDS than after any of the other procedures. However, the major weight loss mechanisms seem to be alterations in metabolic physiology leading to changes in appetite and food preference.
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Weight Loss and Diabetes Mellitus
Gastrointestinal surgery is very effective in securing substantial and durable weight loss, significantly more so than both lifestyle/behavioral and pharmacological measures, as demonstrated by several randomized and observational studies. 11, [44] [45] [46] [47] As an example, a meta-analysis by Chang et al 45 found significant mean BMI reductions at 1 year of 11.8 kg/ m 2 (57 observational studies) and 13.5 kg/m 2 (12 randomized controlled trials) in patients who underwent metabolic surgery. In another meta-analysis (11 randomized controlled trials, 796 obese patients), the authors reported a 26-kg greater weight reduction in patients who underwent metabolic surgery than in those who were subjected to nonsurgical measures alone (95% CI, −31 to −21; P<0.001).
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Although follow-up has been limited to ≤2 years in most studies, long-term data, arbitrarily defined as >5 years, have become increasingly available. 48 As an example, a prospective, observational study of RYGB in the United States recently reported 12-year outcomes for 1156 patients with severe obesity and found mean adjusted changes from baseline in body weight of −35.0 kg in patients who underwent surgery, −2.9 kg in patients who sought but did not undergo surgery, and 0 kg in patients who did not seek surgery (P<0.001 for both comparisons between surgery and no surgery). 49 In the prospective, controlled SOS study (Swedish Obese Subjects), 10-and 15-year mean weight losses were 25% and 27% for RYGB and 14% and 13% for banding procedures versus 1% at both follow-up intervals for matched controls. [50] [51] [52] Similar results were obtained at 20 years, though the authors advised caution in interpretation because of the limited number of patients who had completed extended follow-up. 52 Five-year outcomes are also available from 3 randomized controlled trials that demonstrated sustained weight reduction after RYGB, SG, and biliopancreatic diversion when compared with medical therapy. [53] [54] [55] Likewise, there is abundant evidence supporting the efficacy of these procedures in treating type 2 diabetes mellitus. [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] Indeed, patients with type 2 diabetes mellitus who undergo metabolic surgery often achieve diabetes mellitus remission. The American Diabetes Association defines complete diabetes mellitus remission as a glycated hemoglobin (HbA 1c ) <6.0% or fasting plasma glucose <100 mg/dL without active pharmacological treatment for at least 12 months. Among those with a diagnosis of type 2 diabetes mellitus at baseline in the observational study by Adams et al, 49 12-year diabetes mellitus remission rates were 51% after RYGB, 10% in patients who pursued but did not undergo surgery, and 5% in those who did not pursue surgery (P<0.001 for both comparisons between surgery and nonsurgery). In the SOS study, 15-year diabetes mellitus remission rates were also substantially higher among individuals who underwent surgery versus those who did not (30% versus 7%). 70 Moreover, both studies found that metabolic surgery was effective in preventing diabetes mellitus. 49 , 71 Mingrone et al 58 randomized 60 patients with type 2 diabetes mellitus lasting ≥5 years and a BMI ≥35 kg/m 2 1:1:1 to receive RYGB, biliopancreatic diversion, or medical therapy alone. At 5 years, the primary end point of diabetes mellitus remission, defined as fasting plasma glucose ≤100 mg/dL and HbA 1c ≤6.5%, was reached by 37% of patients in the RYGB group, 63% in the biliopancreatic diversion group, and none in the medical treatment group (P<0.001). 53 The STAMPEDE (Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently) investigators randomized 150 patients with type 2 diabetes mellitus and a BMI 27 to 43 kg/m 2 1:1:1 to RYGB, SG, or intensive medical therapy. 57 Five-year rates of the primary outcome, HbA 1c ≤6.0%, were 29% after RYGB, 23% after SG, and 5% in those who only received medical therapy (P=0.01 for RYGB versus medical therapy, P=0.03 for SG versus medical therapy). 54 composite end point of an HbA 1c <7.0%, a low-density lipoprotein cholesterol <100 mg/dL, and a systolic blood pressure <130 mm Hg was significantly more common in the RYGB group (23% versus 4%; P=0.01).
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Metabolic Surgery and Hypertension
Although most research has focused on the glucometabolic effects of metabolic surgery, there has been a growing interest in exploring the potential blood pressure-reducing properties of these procedures. Indeed, systematic reviews and meta-analyses based primarily on observational data have suggested that metabolic surgery may aid in controlling hypertension. 12 12 in which the authors found a 64% resolution or improvement of hypertension after metabolic surgery. The efficacy of SG appears to lie between that of AGB and RYGB. 75 To date, only one controlled trial specifically evaluating weight loss surgery in patients with obesity and hypertension has been completed. 78 In the GATEWAY trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension), 100 individuals with a BMI 30 to 39.9 kg/m 2 who were treated with ≥2 antihypertensive agents at maximum doses or >2 agents at moderate doses were randomized 1:1 to receive either RYGB plus medical therapy (n=50) or medical therapy alone (n=50). 79 Those with known cardiovascular disease or poorly controlled type 2 diabetes mellitus were excluded. At 12 months, the primary outcome, a ≥30% reduction of the total number of blood pressure medications while maintaining office blood pressure <140/90 mm Hg, had occurred in significantly more patients in the RYGB group compared with controls (83.7% versus 12.8%; rate ratio, 6.6; 95% CI, 3.1-14.0; P<0.001). Remission of hypertension, defined as blood pressure <140/90 mm Hg without medication use, was observed in 51% versus 0% when using office blood pressures and in 46% versus 0% when using 24-hour ambulatory blood pressures. Interestingly, one-third of the subjects in the RYGB group also achieved a modified primary end point using the target blood pressure from the SPRINT (Systolic Blood Pressure Intervention Trial), that is, systolic blood pressure <120 mm Hg. 80 Although 6 participants in the RYGB group required hospitalization during follow-up, only 2 of these were because of procedural complications, and only 1 needed reoperation. A substudy from the GATEWAY trial found similar blood pressure profiles in the 2 groups but significantly lower average real variability of systolic night time . 79 The primary end point was defined as a reduction of ≥30% of the number of antihypertensive medications while maintaining office systolic and diastolic blood pressures <140 and <90 mm Hg, respectively. B, The primary end point (modified according to SPRINT [Systolic Blood Pressure Intervention Trial] treatment targets) with RYGB versus medical therapy in the GATEWAY trial. 79 The modified primary end point was defined as a reduction of ≥30% of the number of antihypertensive medications while maintaining office systolic blood pressures <120 mm Hg. C, Remission of hypertension (office blood pressure) with RYGB versus medical therapy in the GATEWAY trial. 79 Remission of hypertension was defined as office systolic and diastolic blood pressures <140 and <90 mm Hg, respectively, without antihypertensive medications. D, Remission of hypertension (24-hour ambulatory blood pressure monitoring) with RYGB versus medical therapy in the GATEWAY trial. 79 Remission of hypertension was defined as 24-ambulatory systolic and diastolic blood (Continued) Figure 2 Continued. pressures <140 and <90 mm Hg, respectively, without antihypertensive medications. OBP indicates office blood pressure.
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blood pressure, less use of antihypertensive medications, and lower occurrence of resistant hypertension 12 months after RYGB. 81, 82 The main findings from the GATEWAY trial are summarized in Figure 2 .
Long-term data are mainly available from observational studies. 49, 50, 83 Indeed, the contributions of the SOS group extend to hypertension. At a median 10-year follow-up duration, these investigators observed a significantly greater reduction in both systolic and diastolic office-based blood pressures in patients who underwent RYGB versus nonsurgically treated controls (RYGB, −5.1 and −5.6 mm Hg; controls, +1.2 and −3.8 mm Hg; P<0.01 for difference between RYGB and controls). 83 In addition, the proportion of patients on antihypertensive medication was significantly lower in the RYGB group compared with controls (35% versus 53%; P<0.001). Interestingly, a significant linear, positive relationship between changes in blood pressure and changes in BMI was seen at 2 years, but not at 10 years. Such significant relationships were not observed for diastolic blood pressure. Adams et al 49 also found favorable blood pressure profiles 12 years after RYGB compared with nonsurgery; however, this was caused by a roughly neutral effect of surgery, while significantly increasing blood pressures over time (adjusted >6 mm Hg systolic and diastolic) were seen in the 2 control groups (P<0.05 for all comparisons between the RYGB group and controls). Interestingly, the randomized controlled trials by Mingrone et al, 53 Schauer et al, 54 and Ikramuddin et al, 55 respectively, did not find significant long-term benefits on office blood pressure with metabolic surgery versus medical treatment, though clear trends were observed in the latter study (attained primary blood pressure outcome of systolic blood pressure <130 mm Hg at 5 years, RYGB 73% versus lifestyle and intensive medical management 49%; odds ratio, 2.71; 95% CI, 0.95-7.78; P=0.06). Of course, differential add on antihypertensive therapy in the control arms could explain the lack of significant effects of metabolic surgery on blood pressure in these trials.
Pathophysiological Mechanisms
Recognizing that the underlying mechanism for hypertension among subjects with obesity remains uncertain, the reason for improved blood pressure control after metabolic surgery appears to be complex and multifactorial. 84, 85 Analogous to the effects of surgery on glycemic regulation, blood pressure reduction emerges as early as 1 week postoperatively, that is, before the occurrence of any significant weight loss, proposing a role for hormonal mechanisms. 86 For example, Ahmed et al 86 found significant reductions in both systolic (9 mm Hg) and diastolic (7 mm Hg) blood pressure 7 days after RYGB, changes that were maintained over the 12-month course of the study. Therefore, it is possible that the cardiovascular and metabolic improvements observed after surgery may, in part, be mediated by the same hormones. 87 Because the gastrointestinal tract plays a major role in maintaining glucose homeostasis, several neurohumoral interactions may be involved. 39, 88 Increases in levels of the incretin, glucagon-like peptide-1, have been observed after various types of metabolic surgery. 89, 90 Its main effect is to stimulate postprandial insulin secretion and inhibit glucagon secretion, but it also has several central actions, including hypophagia. 88, 89, 91, 92 Interestingly, the area postrema, one of the circumventricular organs in the fourth ventricle, contains catecholaminergic neurons that respond to glucagon-like peptide-1, suggesting that the sympathetic nervous system might be implicated in the blood pressure-lowering effects of metabolic surgery. 93 The hormone further seems to be important for water and salt homeostasis, with high levels being associated with natriuresis. 94 Other studies have proposed a role for natriuretic peptides as their circulating concentrations are low in patients with obesity and increase after metabolic surgery. [95] [96] [97] Finally, individuals with central obesity have an increased activation of the renin-angiotensin-aldosterone system, which may normalize after surgery. 98, 99 Some of these processes are likely related to insulin sensitivity, either directly or indirectly. Subjects with peripheral obesity only show peripheral insulin resistance, without sodium retention, whereas those with central obesity have higher insulin levels and a greater risk of hypertensive disease. 98 Insulin resistance may also stimulate the sympathetic nervous system, a response attenuated by metabolic surgery. 99, 100 This is particularly important as increased activity of the sympathetic nervous system may be associated with increased cardiovascular risk. 101 Sympathetic activity is optimally assessed using microneurographic recordings and measurement of norepinephrine spillover. 102 Seravalle et al 103 observed a significant reduction in muscle sympathetic nerve activity 6 months after SG, an effect that was maintained at 12 months. They also found a significant improvement in baroreflex control of sympathetic nerve activity. 103, 104 These results are supported by other similar studies examining the effects of AGB and RYGB, respectively. 105, 106 In fact, patients in whom hypertension does not resolve after metabolic surgery have a lower reduction in visceral adipose tissue and the lowest parasympathetic activity. 107 Nevertheless, insulinmediated effects cannot be the sole explanation as they do not necessarily occur immediately after surgery. 79 Blood pressure may also be affected by alterations in polypeptides secreted by white adipose tissue, that is, cytokines (adipokines), and systemic and renal inflammation. 108 Woelnerhanssen et al 109 found that circulating leptin levels were almost halved as early as 1 week after RYGB and SG and kept decreasing until 12 months postoperatively, in keeping with the hormone's reflection of total fat mass. The mechanisms involved are complex; although leptin induces satiety, obese individuals also appear to have acquired resistance to its effects. 110 The same investigators reported increasing concentrations of circulating adiponectin, a compound that increases insulin sensitivity, over the course of the study. 109 Concentrations of ghrelin, a potent orexigenic hormone, may increase, decrease, or remain unchanged after metabolic surgery, potentially because of varying degrees of vagal nerve involvement. [111] [112] [113] [114] Interestingly, Falkén et al 115 observed an initial decrease, but subsequent increase to approach preoperative levels. This is particularly important as ghrelin itself may have blood pressure-lowering effects. 116 As insulin sensitivity increases, levels of C-reactive protein and interleukin-6 decrease. 117 In healthy people, perivascular adipose tissue inhibits constriction of small arteries, but this is impaired in patients with obesity, perhaps caused by adipocyte inflammation. 118 The response is restored after metabolic surgery and is paralleled by improvements in inflammatory cytokines, the adipokine profile, and systolic blood pressure. 119 Considering large arteries, visceral white adipose tissue is significantly associated with arterial stiffness, as measured by aortic pulse wave velocity, and weight loss may reduce pulse wave velocity. 120, 121 Finally, the possible resolution of obstructive sleep apnea may be important as several of these mechanisms are linked to this condition.
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Cardiovascular Events and Mortality
A 2011 scientific statement by the AHA Obesity Committee recognized the beneficial metabolic and cardiovascular alterations associated with metabolic surgery and called for more long-term investigations to examine its impact on cardiovascular disease and mortality. 125 A large body of evidence has since accumulated, but while data on cardiovascular risk factors are available from multiple randomized trials, 53, 54, 79 estimates of cardiovascular event rates rely on nonrandomized, observational studies. 74, [126] [127] [128] Besides effects on weight, glycemic status, and blood pressure, metabolic surgery is also associated with improvements in lipid status and target end-organ damage, including favorable changes on various cardiovascular imaging studies. For example, the systematic review by Vest et al 74 reported a 65% resolution or improvement of hyperlipidemia. The same group of authors also examined subjects with obesity and a left ventricular ejection fraction <50% and observed significant improvements after metabolic surgery. 129 Other types of adverse end-organ manifestations that appear to be positively influenced by surgery include left ventricular mass, other structural and functional cardiac indices, urinary albumin excretion, and glomerular filtration rate. [130] [131] [132] [133] [134] [135] In addition, Priester et al 136 conducted a cross-sectional study of patients who had undergone RYGB or no surgery 6 years prior and found significantly lower coronary artery calcium scores in the surgery group. Finally, another cardiovascular risk marker associated with obesity that improves following metabolic surgery is heart rate, including heart rate recovery after exercise and heart rate variability. 137, 138 In the observational Utah Obesity Study, weight loss 2 years after RYGB was associated with a significant decrease in resting heart rate as well as improved heart rate recovery after treadmill exercise when compared with individuals who did not undergo surgery. 137 Considering overt clinical outcomes, Zhou et al 126 performed a meta-analysis of observational studies and found adjusted odds ratios of metabolic surgery versus nonsurgical management for all-cause mortality (10 studies: odds ratio, 0.55; 95% CI, 0.46-0.65), myocardial infarction (1 study: odds ratio, 0.71; 95% CI, 0.54-0.94), stroke (1 study: odds ratio, 0.66; 95% CI, 0.49-0.89), and the combined end point of myocardial infarction or stroke (1 study: odds ratio, 0.67; 95% CI, 0.54-0.83). Supporting these results, Cardoso et al 139 observed a reduction in all-cause mortality at ≥2 years (8 studies: hazard ratio, 0.59; 95% CI, 0.52-0.67; P<0.001) and in cardiovascular mortality (5 studies: hazard ratio, 0.42; 95% CI, 0.25-0.72; P<0.001) with metabolic surgery. These estimates generally relied heavily on the SOS study with its large study population and median follow-up duration of ≈15 years. 51 The SOS investigators also observed significant reductions in atrial fibrillation (adjusted hazard ratio, 0.69; 95% CI, 0.58-0.82; P<0.001). 51, 140 Conversely, a population-based study using different US inpatient databases found a significantly increased risk of emergency department visits or hospitalization for atrial fibrillation for at least 2 years after metabolic surgery (adjusted odds ratio for 0-12 months, 1.53; 95% CI, 1.13-2.07; P=0.006, and for 13-24 months, 1.41; 95% CI, 1.03-1.91; P=0.03). 141 Although weight loss is associated with a decreased risk of atrial fibrillation, the surgical procedures may lead to physiological changes such as a higher sympathetic tone and inflammation, potentially explaining these conflicting results. 142 Finally, metabolic surgery appears to reduce the risk of heart failure. A matched casecontrol study by Benotti et al 128 demonstrated a significantly reduced risk of congestive heart failure at median 6.3 years among people who underwent RYGB versus controls (adjusted hazard ratio, 0.38; 95% CI, 0.22-0.64; P<0.001). These findings were corroborated by a Swedish cohort study in which the 4-year risk of incident heart failure was significantly lower among patients undergoing RYGB compared with those subjected to lifestyle modification (hazard ratio, 0.54; 95% CI, 0.36-0.82). 143 The SOS investigators also reported a decrease in all-cause mortality at mean ≈11 years (adjusted hazard ratio, 0.71; 95% CI, 0.54-0.92; P=0.01). 144 Similarly, a retrospective cohort study using data from the Veteran's Affair health system found a significantly reduced long-term mortality in surgical patients compared with matched controls (baseline to 1 year: adjusted hazard ratio, 1.28; 95% CI, 0.98-1.68; P=0.07, >1 to 5 years: adjusted hazard ratio, 0.45; 95% CI, 0.36-0.56; P<0.001, and >5 to 14 years: adjusted hazard ratio, 0.47; 95% CI, 0.39-0.58; P<0.001). 145 Finally, a retrospective cohort study from Israel showed a significantly reduced 4-year risk of death among surgically versus nonsurgically treated patients, regardless of whether patients underwent SG, RYGB, or ABG.
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Guidelines and Recommendations
International, including North American and European, guidelines recommend metabolic surgery in the following:
1. Patients with a BMI ≥40 kg/m 2 (class III obesity) regardless of coexisting medical conditions. 2. Patients with a BMI 35.0 to 39.9 kg/m 2 (class II obesity) with at least 1 serious comorbidity expected to be improved by weight loss surgery (Table 1) . [147] [148] [149] [150] [151] [152] Some organizations also suggest considering metabolic surgery in patients with a BMI 30 to 34.9 kg/m 2 (class I obesity), type 2 diabetes mellitus, and poor glycemic control. 147, 150, 152 Importantly, the BMI criterion does not necessarily imply use of the current BMI, but may be a previously attained BMI of this severity. Similarly, weight loss because of intensified treatment before surgery, leading to a body weight below the required BMI for surgery, does not contraindicate planned metabolic surgery. 149 Finally, BMI thresholds may be modified depending on patient ancestry. mellitus and cardiovascular disease at BMIs lower than those that conventionally define overweight, but failed to identify a clear cutoff point because of substantial heterogeneity between distinct Asian populations. 154 People of Asian descent also have more visceral fat than white patients of the same BMI. 155 As a result, some organizations suggest that thresholds for metabolic surgery may be lowered by 2.5 kg/m 2 in Asians. 150, 152 A thorough, multidisciplinary approach that assesses metabolic/nutritional, complete physical, and psychological health is crucial in determining eligibility for weight loss surgery. Of course, candidates must have an acceptable surgical risk. 147, 150, 152 The American Society for Metabolic and Bariatric Surgery has published recommendations for preoperative psychosocial evaluation. 156 This document emphasizes the importance of assessing behavioral aspects, such as weight history over time (including previous attempts at weight loss with an inadequate response to behaviorally based therapeutic measures), motivation for weight loss, dietary patterns, physical activity, alcohol or substance abuse, and psychiatric history and cognitive functioning (not understanding the procedure and its risks and benefits). The likelihood of adherence to nutritional supplementation and long-term postoperative follow-up should also be evaluated. 147, 150, 152, 156 Due to the scarcity of evidence from randomized controlled trials directly comparing different types of surgery, it is difficult to simply favor 1 procedure. 147, 150 Some conclusions may be drawn based on the trials by Mingrone et al 53 and Schauer et al, 54 respectively. For instance, biliopancreatic diversion was significantly more effective than RYGB in the study by Mingrone et al, 53 whereas the STAMPEDE trial found a significantly greater efficacy of RYGB versus SG. 54 Other studies that have assessed the differences between specific surgical procedures and provided long-term follow-up include the SLEEVEPASS trial (Sleeve Versus Bypass) and the SM-BOSS (Swiss Multicenter Bypass or Sleeve Study). 157, 158 In the SLEEVEPASS equivalence trial, 240 patients with a BMI >40 or >35 kg/m 2 with a significant obesity-associated comorbidity were randomly allocated to receive either laparoscopic SG or RYGB. 157 At 5 years, the primary end point of mean percentage excess weight loss was 49% after SG and 57% after RYGB. This did not meet the criteria for equivalence, nor was the difference statistically significant. Of note, more patients in the RYGB group discontinued their antihypertensive medications (51% versus 29%; P=0.02). SM-BOSS randomized 217 patients with similar BMI-related inclusion criteria to the same 2 procedures. 158 The primary end point, percentage excess BMI loss, in patients undergoing SG compared with those undergoing RYGB was 61% versus 68% after 5 years, a difference that was not statistically significant either.
Contemporary guidelines suggest that procedural choice be based on individualized therapeutic goals, local expertise, patient preferences, risk stratification, and cost-effectiveness. 147, 150 Laparoscopic approaches are generally preferred over open surgery. Furthermore, there may be regional differences in terms of both procedural volume and choice. According to the 2016 International Federation for the Surgery of Obesity and Metabolic Disorders report, approximately one-third of all surgeries were performed in the United States, a number corroborated by the American Society for Metabolic and Bariatric Surgery, and even though SG accounted for almost half of all procedures performed worldwide, RYGB remained the most common metabolic operation in Latin/South America. 33, 37 In fact, both RYGB and SG appear to have a favorable risk-benefit profile, at least in patients with type 2 diabetes mellitus. 150 In addition, validated scoring tools may help guide the selection between specific procedures. For instance, the Individualized Metabolic Surgery Score allows one to choose between RYGB and SG based on diabetes mellitus duration, number of diabetes mellitus medications, insulin use, and glycemic control. 159 BPDDS is the most, while AGB is the least, effective procedure, and the opposite is true in terms of safety. 150 Recent 5-year data from the PBS (Patient-Centered Clinical Research Network Bariatric Study) further showed that RYGB led to significantly more weight loss than SG. 160 Revision rates for RYGB and SG are similar, but SG is technically simpler and slightly safer, and although AGB is considered the safest procedure, revisions are often necessary. On the other hand, there is a very high risk of nutritional deficits with BPDDS which should only be offered to patients with extreme obesity, usually those with a BMI >60 kg/m 2 . 36, 127, 147, 150 
Safety and Complications
Metabolic surgery is generally considered safe, and over the last decade, mortality rates have decreased by as much as 80%. 161 This positive development is attributed to increased experience, improved patient care protocols, and laparoscopic approaches. 162, 163 Data from the US Nationwide Inpatient Sample database have shown a 0.1% risk of in-hospital mortality, whereas the Longitudinal Assessment of Bariatric Surgery Consortium found a 30-day mortality rate of 0.3%. 164, 165 Similar to lower mortality rates were found in a recent report from England. 166 Chang et al 45 examined a total of 37 randomized controlled trials and found mortality rates of 0.08% within 30 days and 0.31% beyond 30 days. These low figures parallel those 
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observed with hip replacement. 167 The most common causes of death include sepsis (mostly from anastomotic leaks), cardiac causes, and pulmonary embolism. [168] [169] [170] Varying rates of morbidity have been reported, including an in-hospital morbidity rate of 7.1% in the Nationwide Inpatient Sample data collected during 2012 and a 30-day composite morbidity rate of 4.3% in Longitudinal Assessment of Bariatric Surgery. 164, 165 Contributing conditions include cardiovascular events, pulmonary issues, gastrointestinal complications (anastomotic leaks, bowel obstruction, internal hernias, bleeding), infection, nutritional deficiencies, and severe hypoglycemia. 45, 164, 165, 168, 171, 172 Procedure-specific complications are listed in Table 2 . 36, 173, 174 The risk of adverse outcomes depends on patient-related factors (older age, male sex, coexisting disease, greater initial BMI, and smoking), type of operation (degree of invasiveness and procedural duration), the surgeon, and the site (volume of activity). 165, 168, 171 Nutritional deficiencies are very common and most often occur after the procedures with malabsorptive properties, given the surgical modifications leading directly to a reduced intestinal absorptive surface area. 175 In particular, BPDDS may lead to severe protein-calorie malnutrition. 176 Micronutrient deficiencies are caused by both behavioral and physiological factors and may be present preoperatively. Patients may also develop aversion to specific food items postoperatively. 175 Guideline recommendations for postoperative supplementation are shown in Table 3 .
147,177
Postoperative Follow-Up Life-long monitoring is required after metabolic surgery to ensure both success and detection of long-term complications, including nutritional deficiencies and psychosocial changes. 178, 179 Routine exercise and other healthy lifestyle measures should be encouraged. Other factors that may require attention include unhealthful eating patterns and medical conditions, surgical complications, or use of medications that may cause weight gain. Optimally, patients should be managed by a multidisciplinary team involving surgeons, diabetologists/endocrinologists, specialized nurses, and dietitians. Follow-up is recommended at least every 6 months during the first 2 years and at least once a year afterward. 147, 150, 152 
Conclusions and Perspectives
Metabolic surgery is the most effective method to treat obesity and is superior to medical therapy in improving associated hyperglycemic conditions at both short-term and long-term follow-up. A randomized trial specifically examining individuals with obesity and hypertension has further suggested potential benefits of surgery for both remission of hypertension and reduction in the number of antihypertensive medications. 79 Finally, systematic reviews and meta-analyses based on observational data suggest a lowering of both cardiovascular events and mortality after metabolic surgery.
Nevertheless, a few caveats remain, and although international diabetes mellitus organizations have formally included metabolic surgery in their suggested algorithm for treatment of type 2 diabetes mellitus (Figure 3) , 150 its addition to isolated hypertension management algorithms is premature. For instance, an observational study of patients who underwent either RYGB or SG reported a 68% 1-year remission rate of hypertension, but >20% of these individuals had relapsed at 3 years. 180 Moreover, blood pressure control is not improved in all patients. 79 Predictors of such absence of resolution include older age, concomitant diabetes mellitus, less weight loss, and black race. 181 Results from the planned 5-year follow-up of the GATEWAY trial are thus eagerly anticipated. 79 More conclusive data on target end-organ damage and from patients with manifest, specific cardiovascular conditions are 
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March 29, 2019 also underway. The MOMS trial (Microvascular Outcomes After Metabolic Surgery) will improve our understanding of subclinical renal damage by randomly allocating patients with obesity and type 2 diabetes mellitus to RYGB versus best medical treatment, with the primary outcome defined as the proportion of patients who achieve nephropathy remission (urine albumin-creatinine ratio <30 mg/g). 182 Furthermore, the randomized DiaSurg 2 trial (Surgical vs Medical Treatment of Insulin-Dependent Type 2 Diabetes Mellitus in Patients With a Body Mass Index Between 26 and 35 kg/m²) will help clarify long-term clinical risks and benefits by comparing RYGB with standardized medical treatment for a primary composite end point of cardiovascular death, myocardial infarction, coronary bypass, percutaneous coronary intervention, nonfatal stroke, amputation, or surgery for peripheral atherosclerotic artery disease, with a follow-up period of 8 years. 183 Finally, the ARMMS-T2D (Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes) consortium (URL: http://www.clinicaltrials.gov. Unique identifier: NCT02328599) will evaluate long-term outcomes in patients with type 2 diabetes mellitus included in 1 of 4 previously conducted randomized trials.
Accumulating high-quality evidence suggests that the benefits of metabolic surgery for glycemic outcomes may extend to patients who are less obese or even overweight. 54, 57, 72, [184] [185] [186] Therefore, it has become increasingly important to individualize treatment, including procedural choice, based on factors such as concomitant conditions and surgical risk. Although at this point, hypertension cannot be considered the primary indication for performing metabolic surgery, it should be included in the combined risk estimation of patients who are considered candidates for surgery to improve their risk factor burden and reduce their need for medications. 
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